dc.contributor.author | Kucukali, I | |
dc.contributor.author | Sazci, A | |
dc.contributor.author | Ergul, E | |
dc.contributor.author | Kara, I | |
dc.contributor.author | Kaya, G | |
dc.date.accessioned | 2021-03-05T14:52:17Z | |
dc.date.available | 2021-03-05T14:52:17Z | |
dc.date.issued | 2005 | |
dc.identifier.citation | Sazci A., Ergul E., Kucukali I., Kara I., Kaya G., "Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: Association is significant in men but not in women", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, cilt.29, ss.1113-1123, 2005 | |
dc.identifier.issn | 0278-5846 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_b93da3fc-e142-4869-80e6-6933eb3ac102 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/123256 | |
dc.identifier.uri | https://doi.org/10.1016/j.pnpbp.2005.06.022 | |
dc.description.abstract | Schizophrenia is a complex and common psychiatric disorder with a polygenic inheritance. In our previous report, we showed an association between the methylenetetrahydro to I ate reductase (MTHFR) gene C677T and A1298C polymorphisms and schizophrenia in patients from Bakirkoy in Istanbul, Turkey [Sazci, A., Ergul, E., Guzelhan, Y., Kaya, G., Kara, I., 2003. Methylenetetrahydrofolate reductase gene polymorphisms in patients with schizophrenia. Mol. Brain Res. 117, 104-107]. We wanted also independently to confirm this study in a gender-specific manner with schizophrenic patients from Erenkoy in Istanbul, Turkey. To investigate the role of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene in schizophrenia in a gender-specific manner, we analyzed the genotypes of MTHFR677 and MTHFR1298 of 297 schizophrenic patients and 341 healthy controls, using a polymerase chain reaction restriction fragment length polymorphism method. The MTHFR 677T allele was significantly distributed (x(2)=7.3121- P=0.026), between schizophrenic patients and healthy controls. The T677T genotype was overrepresented in the total schizophrenic patients (OR=1.938; 95%CI=1.133-3.315; x(2)=5.996; P=0.014). Similarly, the T677T/AI298A compound genotype was the most significant one in the total schizophrenic patients (OR=2.397; 95% CI=1.327-4.330; x(2) =8.821; P=0.003). The C1298C genotype was overrepresented in the total schizophrenic patients (OR= 1.706; 95%CI=1.014-2.870; x(2) =4.126; P=0.042). Likewise, the C677C/CI298C compound genotype was significant in the total schizophrenic patients (OR=1.689; 95%CI=0.985-2.894; x(2) =3.695; P=0.055). When schizophrenic patients and healthy controls were stratified according to gender difference, the T677T genotype and T677T/AI298A compound genotype were significantly overrepresented (OR-2.184; 95%CI=1.069-4.462; x(2) =4.767; P=0.029; OR=2.748; 95%CI=1.215-6.214; x(2) =6.301; P=0.012, respectively) in men schizophrenic patients. However, neither the MTHFR C677T nor the A I 298C polymorphisms are associated with schizophrenia in women. In conclusion, the MTHFR 677T allele and T677T, C1298C genotypes, and T677T/AI298A, C677C/CI298C compound genotypes are genetic risk factors for schizophrenia in men but not in women in a gender-specific manner. (c) 2005 Elsevier Inc. All rights reserved. | |
dc.language.iso | eng | |
dc.subject | Eczacılık | |
dc.subject | KLİNİK NEUROLOJİ | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Sinirbilim ve Davranış | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Psikiyatri | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Nöroloji | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | NEUROSCIENCES | |
dc.title | Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: Association is significant in men but not in women | |
dc.type | Makale | |
dc.relation.journal | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | |
dc.contributor.department | , , | |
dc.identifier.volume | 29 | |
dc.identifier.issue | 7 | |
dc.identifier.startpage | 1113 | |
dc.identifier.endpage | 1123 | |
dc.contributor.firstauthorID | 38455 | |